Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
Posted on 2022-02-23 - 04:48
Abstract We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.
CITE THIS COLLECTION
Vrba, Lukas; Futscher, Bernard W.; Oshiro, Marc; Watts, George S.; Menashi, Emmanuel; Hu, Charles; et al. (2022): Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. figshare. Collection. https://doi.org/10.6084/m9.figshare.c.5855943.v1
Select your citation style and then place your mouse over the citation text to select it.
Read the peer-reviewed publication
Bernard W. Futscher
George S. Watts
Daniel R. Pennington
Denise J. Roe
Rachna T. Shroff
Mark A. Nelson